Scarica l'app Stockscreener
0.8227
6.57%
0.0507
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.772
Aprire:
$0.8024
Volume 24 ore:
2.82M
Relative Volume:
1.39
Capitalizzazione di mercato:
$5.40M
Reddito:
-
Utile/perdita netta:
$-16.60M
Rapporto P/E:
-0.9244
EPS:
-0.89
Flusso di cassa netto:
$-23.48M
1 W Prestazione:
-61.01%
1M Prestazione:
-73.97%
6M Prestazione:
-85.75%
1 anno Prestazione:
-94.39%
Intervallo 1D:
$0.8024
$0.8422
Intervallo di 1 settimana:
$0.69
$2.1798
Portata 52W:
$0.69
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Nome
Briacell Therapeutics Corp
Settore
Industria
Telefono
(604) 921-1810
Indirizzo
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Confronta BCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.8227 | 19.72M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.63 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.17 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.68 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.33 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.52 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-14 | Iniziato | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie
BCTX files $15M unit offering; share count could triple post-deal | CMCL SEC FilingForm 6-K - Stock Titan
BriaCell Prices $15 Mln Public Offering To Fund Operations And Growth Initiatives - Nasdaq
BriaCell Therapeutics (BCTX) Plunges 61.78% After $15M Public Offering - AInvest
BriaCell (BCTX) Announces $15M Public Offering of Common Shares and Warrants | BCTX Stock News - GuruFocus
BriaCell Therapeutics Announces Pricing of $15 million Public Offering | BCTX Stock News - GuruFocus
BriaCell says $15M unit offering prices at $1.25 per unit - TipRanks
Briacell Therapeutics announces pricing of $15 million public offering - MarketScreener
BriaCell Therapeutics Announces Pricing of $15 million Public Offering - GlobeNewswire
Cancer Immunotherapy Developer BriaCell Secures $15M Funding: What the Deal Means for Investors - Stock Titan
BCTX Stock Surges Amid Positive Developments and Strategic Moves - StocksToTrade
(BCT) Proactive Strategies (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Adds Mayo Clinic to Late-Stage Study in Metastatic Breast Cancer - MarketScreener
BriaCell adds Mayo Clinic to Phase 3 study in metastatic breast cancer - TipRanks
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer - GlobeNewswire
Mayo Clinic Partners with BriaCell for Groundbreaking Phase 3 Breast Cancer Immunotherapy Study - Stock Titan
When the Price of (BCT) Talks, People Listen (BCT:CA) - news.stocktradersdaily.com
BriaCell Shares Slide 22% After Announcing Dilutive Public Offering - MSN
Briacell stock maintains Buy rating at H.C. Wainwright on strong survival data - Investing.com Australia
BriaCell Therapeutics Corp. - Baystreet.ca
BriaCell announces updated Phase 2 survival data fro Bria-IMT - TipRanks
BriaCell’s Bria-IMT Shows Promising Survival Advantage in Metastatic Breast Cancer - TipRanks
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer - GlobeNewswire
Clinical Trial: New Breast Cancer Drug Shows 17.3-Month Survival Rate, Beating Current Standard of Care - Stock Titan
BriaCell Achieves Milestone in Metastatic Breast Cancer Study with Bria-OTS - TipRanks
Promising Clinical Developments and Positive Outlook Justify Buy Rating for BriaCell Therapeutics - TipRanks
BriaCell’s Bria-IMT Shows Promising Results in Advanced Breast Cancer Treatment - TipRanks
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient - Santé log
BriaCell Reports Complete and Sustained Resolution of Brain - GlobeNewswire
Breakthrough: Complete Brain Tumor Resolution in Patient Who Failed 8 Prior Cancer Treatments - Stock Titan
BriaCell Therapeutics Corp (BCTX) Plunges 29.55% Amid Public Offering Concerns - AInvest
BriaCell Therapeutics stock tumbles after announcing public offering By Investing.com - Investing.com South Africa
BriaCell Therapeutics stock tumbles after announcing public offering - Investing.com
BriaCell Plunges 23.33% Amid IPO Registration Amendments - AInvest
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study - Santé log
BriaCell Patient Achieves Sustained Complete Resolution of - GlobeNewswire
Breakthrough: BriaCell's Cancer Therapy Eliminates Lung Metastasis in Advanced Breast Cancer Patient - Stock Titan
BriaCell reports 52% one-year survival rate in metastatic breast cancer trial By Investing.com - Investing.com South Africa
Form FWP BriaCell Therapeutics Filed by: BriaCell Therapeutics Corp. - StreetInsider
BriaCell’s Phase 2 Study Shows Promising Survival Rates in Metastatic Breast Cancer - TipRanks
BriaCell reports 52% one-year survival rate in metastatic breast cancer trial - Investing.com
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer - GlobeNewswire
Breakthrough: New Cancer Drug Shows 52% Survival Rate Where Standard Treatments Failed - Stock Titan
BriaCell Expands Phase 3 Cancer Study with New Clinical Sites - TipRanks
BriaCell Highlights Additional Phase 3 Clinical Sites - GlobeNewswire
BriaCell adds two major cancer centers to Phase 3 breast cancer study - Investing.com
BriaCell’s Phase 3 Study in Metastatic Breast Cancer Receives Positive DSMB Recommendation - TipRanks
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell Reports Increased Losses in Latest Financials - TipRanks
(BCT) Advanced Trading Insights (BCT:CA) - news.stocktradersdaily.com
Briacell Therapeutics Corp expected to post a loss of $1.76 a shareEarnings Preview - TradingView
Learn to Evaluate (BCT) using the Charts (BCT:CA) - news.stocktradersdaily.com
Briacell Therapeutics Corp Azioni (BCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.05%
2.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):